AM 411
Alternative Names: AM-411Latest Information Update: 28 Aug 2026
At a glance
- Originator Altamira Therapeutics
- Class Antirheumatics; Peptides; Small interfering RNA
- Mechanism of Action RELA protein expression modulators; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Switzerland (Parenteral, Injection)
- 02 Jan 2025 Altamira Therapeutics files a provisional patent application for nanoparticle-based circular RNA delivery platform(CycloPhore™)
- 24 Sep 2024 Altamira Therapeutics plans to file an IND application to the US FDA for Rheumatoid arthritis, in 2026